Clinical Trial Update: Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating dalpiciclib with aromatase inhibitors in Luminal B/HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Luminal Breast Cancer

Drugs mentioned

• Aromatase inhibitors (aromatase inhibitor)
• Dalpiciclib (dalpiciclib)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Luminal B/HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN